Organ rejection is a serious problem in private equity.
A PE firm buys a company in Cleveland.
And replaces the head of sales with Trent from New York.
He was some bigshot at GE, they say.
Trent’s from Long Island.
He likes to mention that fact with some regularity.
The sales team is tired of hearing about how things work “in New York.” This is Cleveland.
Six months later the PE firm realizes its Trent mistake, fires him, and promotes someone internally to head sales.
Revenue growth is half what they’d forecast.
The MD wishes he’d talked to an M.D.
Because this deal experienced organ rejection.
The organ from New York had a different blood type and the company rejected it.
PE firms need to test for type match before implanting anyone.
We can help with that.
